Information Provided By:
Fly News Breaks for May 4, 2015
BAYRY, ISIS
May 4, 2015 | 11:04 EDT
Piper Jaffray noted that Isis Pharmaceuticals (ISIS) had been indicating a high level of interest in its FXIrx anti-clotting antisense program ahead of announcing its deal with Bayer (BAYRY) and the firm believes the announcement of a partnership pact was generally expected. The firm said it already included "meaningful" economics from the FXI program in its valuation for Isis and maintains a Neutral rating on the stock, which is up 4.6% to $60.92 in morning trading.
News For ISIS;BAYRY From the Last 2 Days
There are no results for your query ISIS;BAYRY